Decreased myostatin in response to a controlled DASH diet is associated with improved body composition and cardiometabolic biomarkers in older adults: results from a controlled-feeding diet intervention study

Cydne A Perry, Gary P Van Guilder, Tammy A Butterick, Cydne A Perry, Gary P Van Guilder, Tammy A Butterick

Abstract

Background: Elevated concentrations of myostatin inhibit muscle growth, function and strength. Myostatin is a mediator of sarcopenia and is associated with insulin resistance. For this study we tested the response of a calorie-restricted Dietary Approaches to Stop Hypertension (DASH) diet on changes in myostatin, follistatin, and mystatin:follistatin ratio levels after 12 weeks in comparison to basline in adults aged 65 years and older. Furthermore we evaluated correlations between changes in myostatin, body composition and cardiometabolic biomarkers in this cohort of older adults.

Methods: This was a controlled-feeding diet intervention study in which females (n = 17) and males (n = 11) aged 65 years and older consumed either 85 g (n = 15) or 170 g (n = 13) of fresh lean beef within a standardized DASH diet for 12-weeks. Myostatin and follistatin concentrations were measured from fasted blood samples collected at 5 timepoints throughout the 12-week feeding intervention period. Correlations were assessed between changes in myostatin and follistatin levels and measures of body composition and cardiometabolic biomarkers.

Results: There were no differences (p > 0.05) in circulating myostatin or follistatin levels between the beef intake groups. However, with beef groups combined myostatin decreased by 17.6% (p = 0.006) and the myostatin-to-follistatin ratio decreased by 16.5% (p < 0.001) in response to the study diet. Decreased myostatin was positively correlated with reductions in waist circumference (R2 = 0.163; p = 0.033) and fat mass (R2 = 0.233; p = 0.009). There was an inverse relationship between decreased myostatin and increased strength-to-weight ratio (R2 = 0.162; p = 0.034). The change in myostatin-to-follistatin ratio was associated with the change in skeletal muscle mass-to-fat mass ratio (R2 = 0.176; p = 0.026). Decreased myostatin was positively correlated with reductions in total cholesterol (R2 = 0.193; p = 0.012), LDL-C (R2 = 0.163; p = 0.031), insulin (R2 = 0.234; p = 0.009), and HOMA-IR (R2 = 0.248; P = 0.007). There was no change (p > 0.05) in circulating follistatin concentrations in response to the diet intervention.

Conclusions: The outcomes from this study suggest that a calorie-restricted DASH diet has the potential to reduce myostatin concentrations in older adults. Furthermore these outcomes support interrelationships between myostatin, body composition and cardiometabolic health in adults aged 65 years and older.

Trial registration: ClinicalTrials.gov; Identifier: NCT04127240 ; Registration Date: 15/10/ 2019.

Keywords: Aging; Body composition; Cardiometabolic health; Diet; Myostatin; Obesity; Sarcopenia.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Schematic of Particiapnt Flow
Fig. 2
Fig. 2
Correlations Between The Percent Decrease In Myostatin and Measures of Body Composition Across the Dietary Intervention
Fig. 3
Fig. 3
Correlations Between The Percent Decrease in Myostatin and Cardiometabolic Biomarkers Across The Dietary Intervention

References

    1. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387(6628):83–90. doi: 10.1038/387083a0.
    1. Sharma M, Kambadur R, Matthews KG, Somers WG, Devlin GP, Conaglen JV, Fowke PJ, Bass JJ. Myostatin, a transforming growth factor-beta superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct. J Cell Physiol. 1999;180(1):1–9. doi: 10.1002/(SICI)1097-4652(199907)180:1.
    1. White TA, LeBrasseur NK. Myostatin and sarcopenia: opportunities and challenges - a mini-review. Gerontology. 2014;60(4):289–293. doi: 10.1159/000356740.
    1. Bergen HR, 3rd, Farr JN, Vanderboom PM, Atkinson EJ, White TA, Singh RJ, Khosla S, LeBrasseur NK. Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: insights using a new mass spectrometry-based assay. Skelet Muscle. 2015;5:21. doi: 10.1186/s13395-015-0047-5.
    1. Han DS, Chen YM, Lin SY, Chang HH, Huang TM, Chi YC, Yang WS. Serum myostatin levels and grip strength in normal subjects and patients on maintenance haemodialysis. Clin Endocrinol. 2011;75(6):857–863. doi: 10.1111/j.1365-2265.2011.04120.x.
    1. Fife E, Kostka J, Kroc Ł, Guligowska A, Pigłowska M, Sołtysik B, Kaufman-Szymczyk A, Fabianowska-Majewska K, Kostka T. Relationship of muscle function to circulating myostatin, follistatin and GDF11 in older women and men. BMC Geriatr. 2018;18(1):200. doi: 10.1186/s12877-018-0888-y.
    1. Chen MJ, Han DS, Yang JH, Yang YS, Ho HN, Yang WS. Myostatin and its association with abdominal obesity, androgen and follistatin levels in women with polycystic ovary syndrome. Hum Reprod. 2012;27(8):2476–2483. doi: 10.1093/humrep/des209.
    1. Amor M, Itariu BK, Moreno-Viedma V, Keindl M, Jürets A, Prager G, Langer F, Grablowitz V, Zeyda M, Stulnig TM. Serum Myostatin is Upregulated in obesity and correlates with insulin resistance in humans. Exp Clin Endocrinol Diabetes. 2019;127(8):550–556. doi: 10.1055/a-0641-5546.
    1. Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: part I. increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr. 2009;4(2):113–119. doi: 10.1111/j.1559-4572.2008.00044.x.
    1. Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol. 2018;14(9):513–537. doi: 10.1038/s41574-018-0062-9.
    1. St-Onge MP, Gallagher D. Body composition changes with aging: the cause or the result of alterations in metabolic rate and macronutrient oxidation? Nutrition. 2010;26(2):152–155. doi: 10.1016/j.nut.2009.07.004.
    1. Al-Sofiani ME, Ganji SS, Kalyani RR. Body composition changes in diabetes and aging. J Diabetes Complications. 2019;33(6):451–459. doi: 10.1016/j.jdiacomp.2019.03.007.
    1. Wang M, Tan Y, Shi Y, Wang X, Liao Z, Wei P. Diabetes and Sarcopenic obesity: pathogenesis, diagnosis, and treatments. Front Endocrinol (Lausanne) 2020;11:568. doi: 10.3389/fendo.2020.00568.
    1. Guo F, Moellering DR, Garvey WT. The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity. Obesity (Silver Spring) 2014;22(1):110–118. doi: 10.1002/oby.20585.
    1. Eilers W, Chambers D, Cleasby M, Foster K. Local myostatin inhibition improves skeletal muscle glucose uptake in insulin-resistant high-fat diet-fed mice. Am J Physiol Endocrinol Metab. 2020;319(1):E163–E174. doi: 10.1152/ajpendo.00185.2019.
    1. Elashry MI, Eldaey A, Glenske K, Matsakas A, Wenisch S, Arnhold S, Patel K. The effect of high-fat diet on the morphological properties of the forelimb musculature in hypertrophic myostatin null mice. J Anat. 2019;235(4):825–835. doi: 10.1111/joa.13025.
    1. Yan H, Meng J, Zhang S, Zhuang H, Song Y, Xiao X, Wang DW, Jiang J. Pretreatment of rAAV-mediated expression of Myostatin Propeptide lowers type 2 diabetes incidence in C57BL/6 mice on a high-fat diet. Hum Gene Ther. 2019;30(5):661–671. doi: 10.1089/hum.2018.140.
    1. Perry CA, Van Guilder GP, Kauffman A, Hossain M. A calorie-restricted DASH diet reduces body fat and maintains muscle strength in obese older adults. Nutrients. 2019;12(1):102. doi: 10.3390/nu12010102.
    1. Perry CA, Van Guilder GP, Hossain M, Kauffman A. Cardiometabolic changes in response to a calorie-restricted DASH diet in obese older adults. Front Nutr. 2021;8:647847. doi: 10.3389/fnut.2021.647847.
    1. National Heart, Lung, and blood institute, DASH Eating Plan Available Online: . [Accessed 7 March 2017].
    1. 2015–2020 Dietary Guidelines: Appendix 2. Estimated Calorie Needs per Day, by Age, Sex, and Physical Activity Level. Available Online: . [Accessed 7 March 2017].
    1. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419. doi: 10.1007/BF00280883.
    1. Bhatt SP, Nigam P, Misra A, Guleria R, Luthra K, Jain SK, Qadar Pasha MA. Association of the Myostatin gene with obesity, abdominal obesity and low lean body mass and in non-diabetic Asian Indians in north India. PLoS One. 2012;7(8):e40977. doi: 10.1371/journal.pone.0040977.
    1. Allen DL, Cleary AS, Speaker KJ, Lindsay SF, Uyenishi J, Reed JM, Madden MC, Mehan RS. Myostatin, activin receptor IIb, and follistatin-like-3 gene expression are altered in adipose tissue and skeletal muscle of obese mice. Am J Physiol Endocrinol Metab. 2008;294(5):E918–E927. doi: 10.1152/ajpendo.00798.2007.
    1. Hittel DS, Berggren JR, Shearer J, Boyle K, Houmard JA. Increased secretion and expression of myostatin in skeletal muscle from extremely obese women. Diabetes. 2009;58:30–38. doi: 10.2337/db08-0943.
    1. Mcpherron AC, Lee SJ. Suppression of body fat accumulation in myostatin-deficient mice. J Clin Inves. 2002;109:595–601. doi: 10.1172/jci13562.
    1. Zhao B, Wall RJ, Yang J. Transgenic expression of myostatin propeptide prevents diet-induced obesity and insulin resistance. Biochem Biophys Res Commun. 2005;337:248–255. doi: 10.1016/j.bbrc.2005.09.044.
    1. Guo T, Jou W, Chanturiya T, Portas J, Gavrilova O, McPherron AC. Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity. PLoS One. 2009;4(3):e4937. doi: 10.1371/journal.pone.0004937.
    1. Zhang C, McFarlane C, Lokireddy S, Bonala S, Ge X, Masuda S, Gluckman PD, Sharma M, Kambadur R. Myostatin-deficient mice exhibit reduced insulin resistance through activating the AMP-activated protein kinase signalling pathway. Diabetologia. 2011;54(6):1491–1501. doi: 10.1007/s00125-011-2079-7.
    1. Lebrasseur NK. Building muscle, browning fat and preventing obesity by inhibiting myostatin. Diabetologia. 2012;55(1):13–17. doi: 10.1007/s00125-011-2361-8.
    1. Milan G, Dalla Nora E, Pilon C, Pagano C, Granzotto M, Manco M, Mingrone G, Vettor R. Changes in muscle myostatin expression in obese subjects after weight loss. J Clin Endocrinol Metab. 2004;89(6):2724–2727. doi: 10.1210/jc.2003-032047.
    1. Park JJ, Berggren JR, Hulver MW, Houmard JA, Hoffman EP. GRB14, GPD1, and GDF8 as potential network collaborators in weight loss-induced improvements in insulin action in human skeletal muscle. Physiol Genomics. 2006;27:114–121. doi: 10.1152/physiolgenomics.00045.2006.
    1. Léger B, Derave W, De Bock K, Hespel P, Russell AP. Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation. Rejuvenation Res. 2008;11:163–175b. doi: 10.1089/rej.2007.0588.
    1. Patel HP, Al-Shanti N, Davies LC, Barton SJ, Grounds MD, Tellam RL, Stewart CE, Cooper C, Sayer AA. Lean mass, muscle strength and gene expression in community dwelling older men: findings from the Hertfordshire sarcopenia study (HSS) Calcif Tissue Int. 2014;95:308–316. doi: 10.1007/s00223-014-9894-z.
    1. Yarasheski KE, Bhasin S, Sinha-Hikim I, Pak-Loduca J, Gonzalez-Cadavid NF. Serum myostatin-immunoreactive protein is increased in 60-92 year old women and men with muscle wasting. J Nutr Health Aging. 2002;6:343–348.
    1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988(37):1595–607. 10.2337/diab.37.12.1595.
    1. Centers for Disease Control and Prevention. Available Online: [Accessed 28 December 21].
    1. Tu P, Bhasin S, Hruz PW, Herbst KL, Castellani LW, Hua N, Hamilton JA, Guo W. Genetic disruption of myostatin reduces the development of proatherogenic dyslipidemia and atherogenic lesions in Ldlr null mice. Diabetes. 2009;58(8):1739–1748. doi: 10.2337/db09-0349.
    1. Arpaci H. Major determinants of circulating myostatin in polycystic ovary syndrome. Exp Ther Med. 2019;17(2):1383–1389. doi: 10.3892/etm.2018.7080.
    1. Hjorth M, Pourteymour S, Görgens SW, Langleite TM, Lee S, Holen T, Gulseth HL, Birkeland KI, Jensen J, Drevon CA, Norheim F. Myostatin in relation to physical activity and dysglycaemia and its effect on energy metabolism in human skeletal muscle cells. Acta Physiol (Oxf) 2016;217(1):45–60. doi: 10.1111/apha.12631.
    1. Ryan AS, Li G, Blumenthal JB, Ortmeyer HK. Aerobic exercise + weight loss decreases skeletal muscle myostatin expression and improves insulin sensitivity in older adults. Obesity (Silver Spring) 2013;21(7):1350–1356. doi: 10.1002/oby.20216.
    1. Antony N, Bass JJ, Mcmahon CD, Mitchell MD. Myostatin regulates glucose uptake in BeWo cells. Am J Physiol Endocrinol Metab. 2007;293:E1296–E1302. doi: 10.1152/ajpendo.00331.2007.
    1. Assyov YS, Velikova TV, Kamenov ZA. Myostatin and carbohydrate disturbances. Endocr Res. 2017;42:102–109. doi: 10.1080/07435800.2016.1198802.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir